{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T17:39:23Z","timestamp":1765129163848,"version":"3.46.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijcrp.2025.200511","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:56:42Z","timestamp":1757573802000},"page":"200511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of outcomes of direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6288-9090","authenticated-orcid":false,"given":"Bing","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijcrp.2025.200511_bib1","doi-asserted-by":"crossref","first-page":"1099\u223c1101","DOI":"10.1016\/j.mayocp.2020.04.023","article-title":"End-stage renal disease, nonvalvular atrial fibrillation, and the warfarin dilemma","volume":"95","author":"Mcbane","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200511_bib2","doi-asserted-by":"crossref","first-page":"306\u223c316","DOI":"10.5853\/jos.2020.01886","article-title":"Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences","volume":"22","author":"Goel","year":"2020","journal-title":"Journal of Stroke"},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200511_bib4","doi-asserted-by":"crossref","first-page":"181\u223c189","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib5","doi-asserted-by":"crossref","first-page":"341\u223c351","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2021","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ijcrp.2025.200511_bib6","article-title":"Use of non-vitamin k antagonists oral anticoagulants in atrial fibrillation patients on dialysis","volume":"9","author":"Li","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"12","key":"10.1016\/j.ijcrp.2025.200511_bib7","doi-asserted-by":"crossref","first-page":"1139\u223c1151","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijcrp.2025.200511_bib8","doi-asserted-by":"crossref","first-page":"883\u223c891","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcrp.2025.200511_bib9","doi-asserted-by":"crossref","first-page":"981\u223c992","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ijcrp.2025.200511_bib10","doi-asserted-by":"crossref","first-page":"2093\u223c2104","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcrp.2025.200511_bib11","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research Ed.)"},{"key":"10.1016\/j.ijcrp.2025.200511_bib12","article-title":"ROBINS-i: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical research Ed.)"},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the journal of clinical epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib14","doi-asserted-by":"crossref","first-page":"296\u223c309","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin k antagonist phenprocoumon in patients on chronic hemodialysis: the axadia-afnet 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ijcrp.2025.200511_bib15","doi-asserted-by":"crossref","first-page":"1735\u223c1745","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249940","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study","volume":"16","author":"Lin","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200511_bib17","doi-asserted-by":"crossref","first-page":"689\u223c696","DOI":"10.1111\/ejh.13599","article-title":"Safety of apixaban compared to warfarin in hemodialysis patients: do antiplatelets make a difference?","volume":"106","author":"Ionescu","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200511_bib18","doi-asserted-by":"crossref","first-page":"1474\u223c1483","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin k antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"DE Vriese","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200511_bib19","doi-asserted-by":"crossref","first-page":"671\u223c677","DOI":"10.1097\/FJC.0000000000000911","article-title":"Efficacy and safety of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease stage g4: a single-center experience","volume":"76","author":"Heleniak","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"17","key":"10.1016\/j.ijcrp.2025.200511_bib20","doi-asserted-by":"crossref","first-page":"1384\u223c1392","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ijcrp.2025.200511_bib21","doi-asserted-by":"crossref","first-page":"1519\u223c1529","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200511_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019638","article-title":"Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study","volume":"8","author":"Loo","year":"2018","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib23","doi-asserted-by":"crossref","first-page":"412\u223c419","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.ijcrp.2025.200511_bib24","doi-asserted-by":"crossref","first-page":"24\u223c36","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the engage af-timi 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ijcrp.2025.200511_bib25","doi-asserted-by":"crossref","first-page":"972\u223c979","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ijcrp.2025.200511_bib26","doi-asserted-by":"crossref","first-page":"961\u223c970","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a re-ly (randomized evaluation of long-term anticoagulation therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcrp.2025.200511_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of j-rocket af for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circ. J.: Official Journal of the Japanese Circulation Society"},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200511_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17474086.2021.1920012","article-title":"Real-world comparison of direct-acting oral anticoagulants and vitamin k antagonists in chronic kidney disease: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2021","journal-title":"Expert Review of Hematology"},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200511_bib29","doi-asserted-by":"crossref","first-page":"410\u223c419","DOI":"10.21037\/cdt.2019.07.09","article-title":"Net clinical benefit of non-vitamin k antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase iii clinical trials","volume":"9","author":"Gu","year":"2019","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.ijcrp.2025.200511_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.885548","article-title":"Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis","volume":"9","author":"Rhee","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"8","key":"10.1016\/j.ijcrp.2025.200511_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034176","article-title":"Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis","volume":"13","author":"Kao","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcrp.2025.200511_bib32","doi-asserted-by":"crossref","first-page":"45\u223c52","DOI":"10.1016\/j.ejim.2023.08.020","article-title":"Efficacy and safety of direct oral anticoagulants vs vitamin k antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: a systematic review and meta-analysis","volume":"119","author":"Kyriakoulis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"issue":"5","key":"10.1016\/j.ijcrp.2025.200511_bib33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.ajkd.2021.02.328","article-title":"Oral anticoagulant agents in patients with atrial fibrillation and ckd: a systematic review and pairwise network meta-analysis","volume":"78","author":"Su","year":"2021","journal-title":"Am. J. Kidney Dis.: The Official Journal of the National Kidney Foundation"},{"issue":"4","key":"10.1016\/j.ijcrp.2025.200511_bib34","first-page":"335\u223c337","article-title":"Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy[J]. Turk Kardiyoloji Dernegi Arsivi","volume":"44","author":"Kaya","year":"2016","journal-title":"Turk Kardiyoloji Derneginin Yayin Organidir"},{"issue":"2","key":"10.1016\/j.ijcrp.2025.200511_bib35","first-page":"396\u223c398","article-title":"Series with complete resolution of left atrial appendage thrombi with apixaban in elderly patients","volume":"31","author":"Lee","year":"2016","journal-title":"Kor. J. Intern. Med."},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200511_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1590\/1806-9282.66.6.842","article-title":"Fibrinogen and d-dimer variances and anticoagulation recommendations in covid-19: current literature review","volume":"66","author":"Hayiro\u011flu","year":"1992","journal-title":"Revista Da Associacao Medica Brasileira"},{"issue":"6","key":"10.1016\/j.ijcrp.2025.200511_bib37","doi-asserted-by":"crossref","first-page":"364\u223c371","DOI":"10.3109\/07853890.2014.912835","article-title":"Hypercoagulability, d-dimer and atrial fibrillation: an overview of biological and clinical evidence","volume":"46","author":"Danese","year":"2014","journal-title":"Ann. Med."}],"container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487525001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487525001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T17:36:56Z","timestamp":1765129016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772487525001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S2772487525001497"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200511","relation":{},"ISSN":["2772-4875"],"issn-type":[{"type":"print","value":"2772-4875"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of outcomes of direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Cardiovascular Risk and Prevention","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200511"}}